Objective Systemic lupus erythematosus (SLE) is associated with increased susceptibility to infections, including herpes ...

Objective Simple measures of type I interferon (IFN) activity constitute highly attractive biomarkers in systemic lupus erythematosus (SLE). We explore galectin-3-binding protein (G3BP) as a novel ...

Objectives Effective, well-tolerated therapies are needed for SLE. Deucravacitinib is an oral, selective tyrosine kinase 2 (TYK2) inhibitor under evaluation in phase 3 SLE studies. Deucravacitinib ...

Objective No studies have investigated the incidence and correlation of scarring and dyspigmentation across all cutaneous lupus erythematosus (CLE) categories and subtypes. As better characterisation ...

Objectives There is limited data on the clinical manifestations, serologic profile and outcomes of patients with APS in the Philippine setting. This study aimed to determine the clinical and serologic ...

Objectives Ianalumab is an afucosylated, fully human IgG1 monoclonal antibody targeting B-cells through a novel dual mechanism of action of enhanced B-cell depletion through antibody-dependent ...

Objectives To describe patterns of glucocorticoid (GC) use, co-morbidities and infections in an ethnically diverse SLE population from a single UK city-region using a population-based primary care ...

Objectives Hematologic abnormalities are common in systemic lupus erythematosus (SLE), both at disease onset and during its progression. We present a case of severe, corticosteroid-refractory ...

Objectives To assess hemostatic parameters in SLE patients in relation to disease activity, kidney involvement and presence of extraglomerular vascular changes in kidney biopsies. Methods This ...

Objectives Complement activation plays a dual role in systemic lupus erythematosus (SLE) and lupus nephritis (LN) pathogenesis: protective through clearance of immune complexes and cellular waste, but ...

Objectives To investigate the antigen specificity and clinical significance of IgA autoantibody subclasses (IgA1 and IgA2) in antiphospholipid syndrome (APS) patients. Methods We measured IgA1 and ...

Objectives Selecting the right treatment for the right patient remains an elusive goal for patients with SLE. We have identified a theragnostic biomarker for response to belimumab following rituximab, ...